Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eledon Pharmaceuticals (ELDN) Net Income towards Common Stockholders (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Net Income towards Common Stockholders readings, the most recent being -$2.1 million for Q4 2017.

  • On a quarterly basis, Net Income towards Common Stockholders rose 43.67% to -$2.1 million in Q4 2017 year-over-year; TTM through Dec 2017 was -$13.1 million, a 25.7% increase, with the full-year FY2025 number at -$42.3 million, down 32.31% from a year prior.
  • Net Income towards Common Stockholders hit -$2.1 million in Q4 2017 for Eledon Pharmaceuticals, up from -$3.0 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$883000.0 in Q2 2016 to a low of -$13.3 million in Q1 2015.
  • Median Net Income towards Common Stockholders over the past 5 years was -$5.7 million (2013), compared with a mean of -$6.0 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: soared 90.14% in 2016 and later crashed 654.93% in 2017.
  • Eledon Pharmaceuticals' Net Income towards Common Stockholders stood at -$5.5 million in 2013, then fell by 12.06% to -$6.2 million in 2014, then tumbled by 77.46% to -$11.0 million in 2015, then skyrocketed by 66.08% to -$3.7 million in 2016, then skyrocketed by 43.67% to -$2.1 million in 2017.
  • The last three reported values for Net Income towards Common Stockholders were -$2.1 million (Q4 2017), -$3.0 million (Q3 2017), and -$6.7 million (Q2 2017) per Business Quant data.